Cargando…

XPF protein levels determine sensitivity of malignant melanoma cells to oxaliplatin chemotherapy: Suitability as a biomarker for patient selection

As the options for systemic treatment of malignant melanoma (MM) increase, the need to develop biomarkers to identify patients who might benefit from cytotoxic chemotherapy becomes more apparent. In preclinical models, oxaliplatin has activity in cisplatin-resistant cells. In this study, we have sho...

Descripción completa

Detalles Bibliográficos
Autores principales: Hatch, Stephanie B, Swift, Lonnie P, Caporali, Simona, Carter, Rebecca, Hill, Esme J, MacGregor, Thomas P, D’Atri, Stefania, Middleton, Mark R, McHugh, Peter J, Sharma, Ricky A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4233955/
https://www.ncbi.nlm.nih.gov/pubmed/23982883
http://dx.doi.org/10.1002/ijc.28454
_version_ 1782344780300156928
author Hatch, Stephanie B
Swift, Lonnie P
Caporali, Simona
Carter, Rebecca
Hill, Esme J
MacGregor, Thomas P
D’Atri, Stefania
Middleton, Mark R
McHugh, Peter J
Sharma, Ricky A
author_facet Hatch, Stephanie B
Swift, Lonnie P
Caporali, Simona
Carter, Rebecca
Hill, Esme J
MacGregor, Thomas P
D’Atri, Stefania
Middleton, Mark R
McHugh, Peter J
Sharma, Ricky A
author_sort Hatch, Stephanie B
collection PubMed
description As the options for systemic treatment of malignant melanoma (MM) increase, the need to develop biomarkers to identify patients who might benefit from cytotoxic chemotherapy becomes more apparent. In preclinical models, oxaliplatin has activity in cisplatin-resistant cells. In this study, we have shown that oxaliplatin forms interstrand crosslinks (ICLs) in cellular DNA and that loss of the heterodimeric structure-specific endonuclease XPF-ERCC1 causes hypersensitivity to oxaliplatin in mammalian cells. XPF deficiency resulted in late S-phase arrest and persistence of double-strand breaks following oxaliplatin treatment. In a panel of 12 MM cell lines, oxaliplatin sensitivity correlated with XPF and ERCC1 protein levels. The knockdown of ERCC1 and XPF protein levels by RNA interference increased sensitivity of cancer cells to oxaliplatin; overexpression of exogenous ERCC1 significantly decreased drug sensitivity. Following immunohistochemical optimization, XPF protein levels were quantified in MM tissue samples from 183 patients, showing variation in expression and no correlation with prognosis. In 57 patients with MM treated with cisplatin or carboplatin, XPF protein levels did not predict the likelihood of clinical response. We propose that oxaliplatin should not be discarded as a potential treatment for MM on the basis of the limited activity of cisplatin in unselected patients. Moreover, we show that XPF-ERCC1 protein levels are a key determinant of the sensitivity of melanoma cells to oxaliplatin in vitro. Immunohistochemical detection of XPF appears suitable for development as a tissue biomarker for potentially selecting patients for oxaliplatin treatment in a prospective clinical trial.
format Online
Article
Text
id pubmed-4233955
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BlackWell Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-42339552014-12-03 XPF protein levels determine sensitivity of malignant melanoma cells to oxaliplatin chemotherapy: Suitability as a biomarker for patient selection Hatch, Stephanie B Swift, Lonnie P Caporali, Simona Carter, Rebecca Hill, Esme J MacGregor, Thomas P D’Atri, Stefania Middleton, Mark R McHugh, Peter J Sharma, Ricky A Int J Cancer Short Report As the options for systemic treatment of malignant melanoma (MM) increase, the need to develop biomarkers to identify patients who might benefit from cytotoxic chemotherapy becomes more apparent. In preclinical models, oxaliplatin has activity in cisplatin-resistant cells. In this study, we have shown that oxaliplatin forms interstrand crosslinks (ICLs) in cellular DNA and that loss of the heterodimeric structure-specific endonuclease XPF-ERCC1 causes hypersensitivity to oxaliplatin in mammalian cells. XPF deficiency resulted in late S-phase arrest and persistence of double-strand breaks following oxaliplatin treatment. In a panel of 12 MM cell lines, oxaliplatin sensitivity correlated with XPF and ERCC1 protein levels. The knockdown of ERCC1 and XPF protein levels by RNA interference increased sensitivity of cancer cells to oxaliplatin; overexpression of exogenous ERCC1 significantly decreased drug sensitivity. Following immunohistochemical optimization, XPF protein levels were quantified in MM tissue samples from 183 patients, showing variation in expression and no correlation with prognosis. In 57 patients with MM treated with cisplatin or carboplatin, XPF protein levels did not predict the likelihood of clinical response. We propose that oxaliplatin should not be discarded as a potential treatment for MM on the basis of the limited activity of cisplatin in unselected patients. Moreover, we show that XPF-ERCC1 protein levels are a key determinant of the sensitivity of melanoma cells to oxaliplatin in vitro. Immunohistochemical detection of XPF appears suitable for development as a tissue biomarker for potentially selecting patients for oxaliplatin treatment in a prospective clinical trial. BlackWell Publishing Ltd 2014-03-15 2013-11-14 /pmc/articles/PMC4233955/ /pubmed/23982883 http://dx.doi.org/10.1002/ijc.28454 Text en © 2013 UICC http://creativecommons.org/licenses/by/3.0/ This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Short Report
Hatch, Stephanie B
Swift, Lonnie P
Caporali, Simona
Carter, Rebecca
Hill, Esme J
MacGregor, Thomas P
D’Atri, Stefania
Middleton, Mark R
McHugh, Peter J
Sharma, Ricky A
XPF protein levels determine sensitivity of malignant melanoma cells to oxaliplatin chemotherapy: Suitability as a biomarker for patient selection
title XPF protein levels determine sensitivity of malignant melanoma cells to oxaliplatin chemotherapy: Suitability as a biomarker for patient selection
title_full XPF protein levels determine sensitivity of malignant melanoma cells to oxaliplatin chemotherapy: Suitability as a biomarker for patient selection
title_fullStr XPF protein levels determine sensitivity of malignant melanoma cells to oxaliplatin chemotherapy: Suitability as a biomarker for patient selection
title_full_unstemmed XPF protein levels determine sensitivity of malignant melanoma cells to oxaliplatin chemotherapy: Suitability as a biomarker for patient selection
title_short XPF protein levels determine sensitivity of malignant melanoma cells to oxaliplatin chemotherapy: Suitability as a biomarker for patient selection
title_sort xpf protein levels determine sensitivity of malignant melanoma cells to oxaliplatin chemotherapy: suitability as a biomarker for patient selection
topic Short Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4233955/
https://www.ncbi.nlm.nih.gov/pubmed/23982883
http://dx.doi.org/10.1002/ijc.28454
work_keys_str_mv AT hatchstephanieb xpfproteinlevelsdeterminesensitivityofmalignantmelanomacellstooxaliplatinchemotherapysuitabilityasabiomarkerforpatientselection
AT swiftlonniep xpfproteinlevelsdeterminesensitivityofmalignantmelanomacellstooxaliplatinchemotherapysuitabilityasabiomarkerforpatientselection
AT caporalisimona xpfproteinlevelsdeterminesensitivityofmalignantmelanomacellstooxaliplatinchemotherapysuitabilityasabiomarkerforpatientselection
AT carterrebecca xpfproteinlevelsdeterminesensitivityofmalignantmelanomacellstooxaliplatinchemotherapysuitabilityasabiomarkerforpatientselection
AT hillesmej xpfproteinlevelsdeterminesensitivityofmalignantmelanomacellstooxaliplatinchemotherapysuitabilityasabiomarkerforpatientselection
AT macgregorthomasp xpfproteinlevelsdeterminesensitivityofmalignantmelanomacellstooxaliplatinchemotherapysuitabilityasabiomarkerforpatientselection
AT datristefania xpfproteinlevelsdeterminesensitivityofmalignantmelanomacellstooxaliplatinchemotherapysuitabilityasabiomarkerforpatientselection
AT middletonmarkr xpfproteinlevelsdeterminesensitivityofmalignantmelanomacellstooxaliplatinchemotherapysuitabilityasabiomarkerforpatientselection
AT mchughpeterj xpfproteinlevelsdeterminesensitivityofmalignantmelanomacellstooxaliplatinchemotherapysuitabilityasabiomarkerforpatientselection
AT sharmarickya xpfproteinlevelsdeterminesensitivityofmalignantmelanomacellstooxaliplatinchemotherapysuitabilityasabiomarkerforpatientselection